메뉴 건너뛰기




Volumn 98, Issue 10, 2013, Pages 1492-1495

Light chain amyloidosis: The heart of the problem

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; SERUM AMYLOID A; THALIDOMIDE;

EID: 84884940241     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.094482     Document Type: Article
Times cited : (79)

References (28)
  • 1
    • 84884933036 scopus 로고    scopus 로고
    • Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
    • Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98(10): 1593-9.
    • (2013) Haematologica , vol.98 , Issue.10 , pp. 1593-1599
    • Dinner, S.1    Witteles, W.2    Afghahi, A.3    Witteles, R.4    Arai, S.5    Lafayette, R.6
  • 2
    • 79955842001 scopus 로고    scopus 로고
    • Amyloidosis: Pathogenesis and new therapeutic options
    • Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-33.
    • (2011) J Clin Oncol , vol.29 , Issue.14 , pp. 1924-1933
    • Merlini, G.1    Seldin, D.C.2    Gertz, M.A.3
  • 3
    • 80052286754 scopus 로고    scopus 로고
    • Cardiac amyloidosis: A treatable disease, often overlooked
    • Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124(9):1079-85.
    • (2011) Circulation , vol.124 , Issue.9 , pp. 1079-1085
    • Falk, R.H.1
  • 4
    • 0035797855 scopus 로고    scopus 로고
    • Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts
    • Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594-7.
    • (2001) Circulation , vol.104 , Issue.14 , pp. 1594-1597
    • Liao, R.1    Jain, M.2    Teller, P.3    Connors, L.H.4    Ngoy, S.5    Skinner, M.6
  • 5
    • 84882528609 scopus 로고    scopus 로고
    • Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
    • Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 2013;108(5):378.
    • (2013) Basic Res Cardiol , vol.108 , Issue.5 , pp. 378
    • Guan, J.1    Mishra, S.2    Shi, J.3    Plovie, E.4    Qiu, Y.5    Cao, X.6
  • 6
    • 84879576449 scopus 로고    scopus 로고
    • Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
    • Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013;305(1):H95-103.
    • (2013) Am J Physiol Heart Circ Physiol , vol.305 , Issue.1
    • Mishra, S.1    Guan, J.2    Plovie, E.3    Seldin, D.C.4    Connors, L.H.5    Merlini, G.6
  • 7
    • 33646597285 scopus 로고    scopus 로고
    • Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
    • Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854-8.
    • (2006) Blood , vol.107 , Issue.10 , pp. 3854-3858
    • Palladini, G.1    Lavatelli, F.2    Russo, P.3    Perlini, S.4    Perfetti, V.5    Bosoni, T.6
  • 8
    • 4644336052 scopus 로고    scopus 로고
    • Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
    • Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
    • (2004) J Clin Oncol , vol.22 , Issue.18 , pp. 3751-3757
    • Dispenzieri, A.1    Gertz, M.2    Kyle, R.3    Lacy, M.4    Burritt, M.5    Therneau, T.6
  • 9
    • 84860643971 scopus 로고    scopus 로고
    • Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    • Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-95.
    • (2012) J Clin Oncol , vol.30 , Issue.9 , pp. 989-995
    • Kumar, S.1    Dispenzieri, A.2    Lacy, M.Q.3    Hayman, S.R.4    Buadi, F.K.5    Colby, C.6
  • 10
    • 78649759752 scopus 로고    scopus 로고
    • Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study
    • Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-82.
    • (2010) Blood , vol.116 , Issue.23 , pp. 4777-4782
    • Moreau, P.1    Jaccard, A.2    Benboubker, L.3    Royer, B.4    Leleu, X.5    Bridoux, F.6
  • 11
    • 84877063628 scopus 로고    scopus 로고
    • Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: Results of a phase II trial
    • Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789-92.
    • (2013) Haematologica , vol.98 , Issue.5 , pp. 789-792
    • Sanchorawala, V.1    Patel, J.M.2    Sloan, J.M.3    Shelton, A.C.4    Zeldis, J.B.5    Seldin, D.C.6
  • 12
    • 84879458198 scopus 로고    scopus 로고
    • A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
    • Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-7.
    • (2013) Blood , vol.121 , Issue.17 , pp. 3420-3427
    • Wechalekar, A.D.1    Schonland, S.O.2    Kastritis, E.3    Gillmore, J.D.4    Dimopoulos, M.A.5    Lane, T.6
  • 13
    • 84876420384 scopus 로고    scopus 로고
    • Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    • Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557-61.
    • (2013) Bone Marrow Transplant , vol.48 , Issue.4 , pp. 557-561
    • Gertz, M.A.1    Lacy, M.Q.2    Dispenzieri, A.3    Kumar, S.K.4    Dingli, D.5    Leung, N.6
  • 14
    • 84863011518 scopus 로고    scopus 로고
    • High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
    • Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-22.
    • (2012) Blood , vol.119 , Issue.5 , pp. 1117-1122
    • Madan, S.1    Kumar, S.K.2    Dispenzieri, A.3    Lacy, M.Q.4    Hayman, S.R.5    Buadi, F.K.6
  • 15
    • 78650987230 scopus 로고    scopus 로고
    • Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    • Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-8.
    • (2011) Mayo Clin Proc , vol.86 , Issue.1 , pp. 12-18
    • Kumar, S.K.1    Gertz, M.A.2    Lacy, M.Q.3    Dingli, D.4    Hayman, S.R.5    Buadi, F.K.6
  • 16
    • 84860895856 scopus 로고    scopus 로고
    • CyBorD: Stellar response rates in AL amyloidosis
    • Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343-5.
    • (2012) Blood , vol.119 , Issue.19 , pp. 4343-4345
    • Merlini, G.1
  • 17
    • 0038518441 scopus 로고    scopus 로고
    • Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
    • Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-5.
    • (2003) Circulation , vol.107 , Issue.19 , pp. 2440-2445
    • Palladini, G.1    Campana, C.2    Klersy, C.3    Balduini, A.4    Vadacca, G.5    Perfetti, V.6
  • 18
    • 84884171906 scopus 로고    scopus 로고
    • Systemic light chain amyloidosis: An update for treating physicians
    • Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-30.
    • (2013) Blood , vol.121 , Issue.26 , pp. 5124-5130
    • Merlini, G.1    Wechalekar, A.D.2    Palladini, G.3
  • 19
    • 84860897399 scopus 로고    scopus 로고
    • Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
    • Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-90.
    • (2012) Blood , vol.119 , Issue.19 , pp. 4387-4390
    • Venner, C.P.1    Lane, T.2    Foard, D.3    Rannigan, L.4    Gibbs, S.D.5    Pinney, J.H.6
  • 21
    • 78149282151 scopus 로고    scopus 로고
    • Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
    • Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93-7.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 93-97
    • Bodin, K.1    Ellmerich, S.2    Kahan, M.C.3    Tennent, G.A.4    Loesch, A.5    Gilbertson, J.A.6
  • 22
    • 84055223035 scopus 로고    scopus 로고
    • Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
    • Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118(25):6610-7.
    • (2011) Blood , vol.118 , Issue.25 , pp. 6610-6617
    • Ward, J.E.1    Ren, R.2    Toraldo, G.3    Soohoo, P.4    Guan, J.5    O'Hara, C.6
  • 23
    • 77955227051 scopus 로고    scopus 로고
    • Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis
    • Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol. 2010;99(8):483-90.
    • (2010) Clin Res Cardiol , vol.99 , Issue.8 , pp. 483-490
    • Mereles, D.1    Buss, S.J.2    Hardt, S.E.3    Hunstein, W.4    Katus, H.A.5
  • 25
    • 78249290790 scopus 로고    scopus 로고
    • Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure
    • Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90(8):905-11.
    • (2010) Transplantation , vol.90 , Issue.8 , pp. 905-911
    • Dey, B.R.1    Chung, S.S.2    Spitzer, T.R.3    Zheng, H.4    Macgillivray, T.E.5    Seldin, D.C.6
  • 26
    • 54049148697 scopus 로고    scopus 로고
    • Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
    • Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143(3):369-73.
    • (2008) Br J Haematol , vol.143 , Issue.3 , pp. 369-373
    • Lebovic, D.1    Hoffman, J.2    Levine, B.M.3    Hassoun, H.4    Landau, H.5    Goldsmith, Y.6
  • 27
    • 60749115105 scopus 로고    scopus 로고
    • Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
    • Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347-50.
    • (2009) Ann Hematol , vol.88 , Issue.4 , pp. 347-350
    • Palladini, G.1    Russo, P.2    Lavatelli, F.3    Nuvolone, M.4    Albertini, R.5    Bosoni, T.6
  • 28
    • 77956051099 scopus 로고    scopus 로고
    • Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
    • Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-8.
    • (2010) Blood , vol.116 , Issue.4 , pp. 522-528
    • Dietrich, S.1    Schonland, S.O.2    Benner, A.3    Bochtler, T.4    Kristen, A.V.5    Beimler, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.